Nemod Immunotherapie Cancer Company Intelligence Report

Pharma Business Daily
Claim your FREE trial subscription!

Cancer:

Nemod Immunotherapie Cancer Company Intelligence Report

Espicom Business Intelligence
Market Briefing September 2005

Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. NEMOD Immuntherapie is a biotechnology company specialised in drug discovery and development in the field of cancer immunotherapy. NEMOD was founded as a spin-off of the Max-Delbrück-Center of Molecular Medicine (MDC) in January 2000 by Dr Steffen Goletz, head of a research group at the MDC, and Dr Andreas Eckert, CEO and founder of Eckert & Ziegler AG. Since January 2002, NEMOD is an affiliated company of Eckert & Ziegler.

Number of pages - 518

For full details, please email keithw@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.